Literature DB >> 1283501

Clinical course of bone metastasis from prostatic cancer following endocrine therapy: examination with bone x-ray.

J Shimazaki1, T Higa, S Akimoto, M Masai, S Isaka.   

Abstract

X-ray findings of bone metastatic lesions from 81 cases of stage D2 prostatic cancer were examined before and following endocrine therapy. Untreated lesions were classified into five types; osteoblastic (15%), mixed, but mainly osteoblastic (31%), mixed, but mainly osteolytic (17%), osteolytic (10%), and undetermined with a positive bone scan (27%). Patients with two mixed types had a tendency of widely speeded areas of metastasis and elevated serum prostatic acid phosphatase. Temporal enlargement of sclerotic lesion immediately after the start of therapy did not indicate disease progression. In many cases, changes from osteolytic to osteoblastic patterns were noticed in the same lesion regardless of the effects of endocrine therapy. Remodeling to the sclerotic pattern appeared as curative changes. From these findings, it was concluded that the natural course of bone lesions showed a tendency to change from the osteolytic to osteoblastic type and relapse was often accompanied by an increase of the osteolytic type lesion. Evaluation of therapeutic effects based on remodeling, changes in number and areas of lesions, and the appearance of new lesion correlated well with prognosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1283501     DOI: 10.1007/978-1-4615-3398-6_29

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  8 in total

Review 1.  Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases.

Authors:  Thomas J Wilson; Rakesh K Singh
Journal:  Biochim Biophys Acta       Date:  2007-11-26

2.  Safety of percutaneous vertebroplasty for the treatment of metastatic spinal tumors in patients with posterior wall defects.

Authors:  Hongpu Sun; Zuozhang Yang; Yongqing Xu; Xuefeng Liu; Ya Zhang; Yanjin Chen; Da Xu; Yihao Yang; Dongqi Li; Junfeng Xia
Journal:  Eur Spine J       Date:  2015-02-19       Impact factor: 3.134

3.  Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis.

Authors:  Michael L Cher; Hector R Biliran; Sunita Bhagat; Yonghong Meng; Mingxin Che; Jaron Lockett; Judith Abrams; Rafael Fridman; Michael Zachareas; Shijie Sheng
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-03       Impact factor: 11.205

4.  Clinical investigations on the spinal osteoblastic metastasis treated by combination of percutaneous vertebroplasty and (125)I seeds implantation versus radiotherapy.

Authors:  Zuozhang Yang; Jing Tan; Ruilian Zhao; Jiaping Wang; Hongpu Sun; Xiaoxue Wang; Lei Xu; Hua Jiang; Jinlei Zhang
Journal:  Cancer Biother Radiopharm       Date:  2012-09-25       Impact factor: 3.099

5.  Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone.

Authors:  Aya Kobayashi; Hiroshi Okuda; Fei Xing; Puspa R Pandey; Misako Watabe; Shigeru Hirota; Sudha K Pai; Wen Liu; Koji Fukuda; Christopher Chambers; Andrew Wilber; Kounosuke Watabe
Journal:  J Exp Med       Date:  2011-11-28       Impact factor: 14.307

6.  Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases.

Authors:  Colm Morrissey; Paul L Kostenuik; Lisha G Brown; Robert L Vessella; Eva Corey
Journal:  BMC Cancer       Date:  2007-08-03       Impact factor: 4.430

7.  Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies.

Authors:  Malin Hagberg Thulin; Karin Jennbacken; Jan-Erik Damber; Karin Welén
Journal:  Clin Exp Metastasis       Date:  2013-12-01       Impact factor: 5.150

8.  Incidental finding of metastatic prostatic adenocarcinoma of frontotemporal bone presenting as subdual hematoma: A case report and review of literature.

Authors:  Kuang-Ting Liu; Yueh-Ching Chang; Junn-Liang Chang
Journal:  Ann Med Surg (Lond)       Date:  2021-12-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.